TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
25 hedge funds and large institutions have $11.6M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 5 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
4% more funds holding
Funds holding: 24 → 25 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
50% less capital invested
Capital invested by funds: $23.2M → $11.6M (-$11.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$142K |
| 2 |
TI
Telemetry Investments
New York
|
+$75.4K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
+$37.6K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$32.1K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$30.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$163K |
| 2 |
BlackRock
New York
|
-$37K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$25K |
| 4 |
Jane Street
New York
|
-$23K |
| 5 |
SBIA
Sheaff Brock Investment Advisors
Indianapolis,
Indiana
|
-$17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Jane Street
New York
| – | -$23K | -84 | Closed |
|
|
SBIA
27
Sheaff Brock Investment Advisors
Indianapolis,
Indiana
| – | -$17K | -63 | Closed |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| – | -$4K | -13 | Closed |
|
|
BAM
29
Bruderman Asset Management
Locust Valley,
New York
| – | -$3K | -10 | Closed |
|
TCON Hedge Fund Activity: Q2 2019 in Review
25 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q2 2019, worth a combined $11.6M — down 50% from $23.2M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TCON positions and 5 closed out — a net gain of 1 holder — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $142K. The largest seller was Vanguard Group, cutting an estimated $163K.
- 25 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q2 2019, up from 24 in Q1 2019.
- Funds reported $11.6M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q2 2019, down 50% quarter-over-quarter.
- 6 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q2 2019 and 5 closed out, a net change of +1 holder.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q2 2019 was Renaissance Technologies, an estimated $142K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q2 2019 was Vanguard Group, an estimated $163K sold.
Based on aggregated 13F filings for Q2 2019.